• 四川大學(xué)華西醫(yī)院普外科（成都610041）;

目的  了解乳腺浸潤(rùn)性導(dǎo)管癌中雌激素調(diào)節(jié)蛋白（PS2）和谷胱甘肽S轉(zhuǎn)移酶π（GSTπ）的表達(dá)及其對(duì)預(yù)后和治療的指導(dǎo)作用。
方法  用標(biāo)記的鏈親和素生物素（LSAB）免疫組化法對(duì)210例乳腺浸潤(rùn)性導(dǎo)管癌患者的石蠟標(biāo)本進(jìn)行PS2和GSTπ的檢測(cè)。
結(jié)果  PS2的表達(dá)陽(yáng)性率為49.5%，GSTπ的表達(dá)陽(yáng)性率為48.1%。術(shù)后5年和10年生存率從高到低依次為PS2表達(dá)陽(yáng)性／GSTπ表達(dá)陰性組、PS2表達(dá)陽(yáng)性／GSTπ表達(dá)陽(yáng)性組、PS2表達(dá)陰性／GSTπ表達(dá)陰性組和PS2表達(dá)陰性／GSTπ表達(dá)陽(yáng)性組。
結(jié)論  PS2表達(dá)陽(yáng)性／GSTπ表達(dá)陰性組患者的預(yù)后最好，PS2表達(dá)陽(yáng)性／GSTπ表達(dá)陽(yáng)性組和PS2表達(dá)陰性/GSTπ表達(dá)陽(yáng)性組患者的預(yù)后次之，PS2表達(dá)陰性／GSTπ表達(dá)陽(yáng)性組患者的預(yù)后最差。因此，在臨床中應(yīng)根據(jù)患者的情況合理應(yīng)用內(nèi)分泌治療和化療。

引用本文： 范偉,楊金巧,伍曉汀. 乳腺浸潤(rùn)性導(dǎo)管癌中PS2和GSTπ的表達(dá)及臨床意義. 中國(guó)普外基礎(chǔ)與臨床雜志, 2004, 11(1): 14-16. doi: 復(fù)制

1. Ledingham IM, Mackey C. International union against cancer TNM classification of malignant tumors [A]. In: Ledingham IM, Mackey C. ed. Surgical Pathology [M]. 4th ed. Edinburgh London Melbourne and New York: Churchill Liringstone. 1998∶85.
2. McCarthy AL, Henry JA, Angns B, et al. Prognostic significance of the estrogenregulated protein, eathepsin D in breast cancer [J]. Cancer, 1990; 65(2)∶265.
3. Gairns J, Wright H, Cattan AR, et al. Immunohistochemical demonstration of glutathinone Stransterase in primary human breast carcinomas [J]. J Pathol, 1992; 166(1)∶19.
4. Tomasetto C.PS2 and breast cancer: a review of the literature [J]. BP: IGBMC, 1997; 163(9)∶19.
5. Gion M, Mione R, Pappagallo GL, et al. PS2 in breast canceralternative or complementary tool to steroid receptor status? Evaluation of 446 cases [J]. Br J Cancer， 1993; 68(2)∶374.
6. 韓小紅， 孫素蓮. PS2一種新乳腺癌預(yù)后預(yù)示因子 [J]. 臨床與實(shí)驗(yàn)病理學(xué)雜志， 1998； 1（8）∶74.
7. 陳高明， 李春海. 乳腺癌中GSTπ和MDR1基因表達(dá)及其臨床價(jià)值 [J].中國(guó)癌癥研究進(jìn)展， 1998； 5（6）∶81.
  1. 1. Ledingham IM, Mackey C. International union against cancer TNM classification of malignant tumors [A]. In: Ledingham IM, Mackey C. ed. Surgical Pathology [M]. 4th ed. Edinburgh London Melbourne and New York: Churchill Liringstone. 1998∶85.
  2. 2. McCarthy AL, Henry JA, Angns B, et al. Prognostic significance of the estrogenregulated protein, eathepsin D in breast cancer [J]. Cancer, 1990; 65(2)∶265.
  3. 3. Gairns J, Wright H, Cattan AR, et al. Immunohistochemical demonstration of glutathinone Stransterase in primary human breast carcinomas [J]. J Pathol, 1992; 166(1)∶19.
  4. 4. Tomasetto C.PS2 and breast cancer: a review of the literature [J]. BP: IGBMC, 1997; 163(9)∶19.
  5. 5. Gion M, Mione R, Pappagallo GL, et al. PS2 in breast canceralternative or complementary tool to steroid receptor status? Evaluation of 446 cases [J]. Br J Cancer， 1993; 68(2)∶374.
  6. 6. 韓小紅， 孫素蓮. PS2一種新乳腺癌預(yù)后預(yù)示因子 [J]. 臨床與實(shí)驗(yàn)病理學(xué)雜志， 1998； 1（8）∶74.
  7. 7. 陳高明， 李春海. 乳腺癌中GSTπ和MDR1基因表達(dá)及其臨床價(jià)值 [J].中國(guó)癌癥研究進(jìn)展， 1998； 5（6）∶81.